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toxic tau oligomers Modulated by 
novel curcumin Derivatives
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The pathological aggregation and accumulation of tau, a microtubule-associated protein, is a common 
feature amongst more than 18 different neurodegenerative diseases that are collectively known as 
tauopathies. Recently, it has been demonstrated that the soluble and hydrophobic tau oligomers are 
highly toxic in vitro due to their capacity towards seeding tau misfolding, thereby propagating the tau 
pathology seen across different neurodegenerative diseases. Modulating the aggregation state of tau 
oligomers through the use of small molecules could be a useful therapeutic strategy to target their 
toxicity, regardless of other factors involved in their formation. In this study, we screened and tested a 
small library of newly synthesized curcumin derivatives against preformed recombinant tau oligomers. 
Our results show that the curcumin derivatives affect and modulate the tau oligomer aggregation 
pathways, converting to a more aggregated non-toxic state as assessed in the human neuroblastoma 
SH-SY5Y cell line and primary cortical neuron cultures. These results provide insight into tau 
aggregation and may become a basis for the discovery of new therapeutic agents, as well as advance 
the diagnostic field for the detection of toxic tau oligomers.
Millions of people worldwide are affected by age-related tauopathies, including Alzheimer’s disease (AD), 
which are characterized by the pathological accumulation of tau aggregates1–3. Tau is a natively unfolded protein 
involved in microtubule stabilization and axonal transport. However, under pathological conditions, tau detaches 
from the microtubules, causing their instability and disassembly. As a consequence of this detachment, there is a 
perturbation of cytoskeletal stability and axonal transport4,5. Unbound tau can self-aggregate to form soluble oli-
gomers (TauO) that combine into paired helical filaments (PHFs)6–8. The PHFs then aggregate into large insoluble 
fibrils, known as neurofibrillary tangles (NFTs)9. Although NFTs have been assumed to be the main pathological 
hallmark in tauopathies, recent studies have demonstrated that the accumulation of the smaller, soluble and 
dynamic tau oligomers, as well as neuronal loss, precede the formation of NFTs and the clinical manifestation of 
AD symptomatology10,11. These evidences suggest that tau oligomers are the toxic entities playing a crucial role for 
disease onset and acting as an efficient seed in the misfolding and the propagation of the pathology12,13. Moreover, 
this evidence supports tau as being a potential target for the development of successful disease-modifying thera-
peutics1,14. Unfortunately, the aggregation and subsequent internalization of misfolded proteins by cells, and their 
spreading into neighboring or anatomically connected cells, contributes to what makes the treatment of tauopa-
thies difficult15,16. This phenomena highlights the need to diagnose these disorders earlier and more effectively 
to begin treatment prior to the initiation and spread of the pathology17–19. Despite tau being an intracellularly 
expressed protein, increasing evidence suggests the presence of extracellular tau aggregates and their role in tau 
propagation. Thus, it has been proposed that extracellular treatments may be as equally important as intracellular 
treatments in disease prevention20–25. In recent years, tau aggregation inhibitors have been a focus of great inter-
est as potential disease-modifying drugs. The search for non-toxic tau aggregation inhibitors capable of easily 
crossing the Brain-Blood-Barrier (BBB) have led to the discovery of several synthetic, as well as naturally occur-
ring, small molecules able to inhibit amyloidogenic protein aggregation23,26–29. Curcumin, which is a polyphe-
nol extracted from the plant Curcuma longa, has been shown to play an important role in the prevention and 
treatment of many diseases, including neurodegenerative disorders30–33.It has been demonstrated that curcumin 
alters the misfolding of many amyloid proteins through the disruption of π-stacking due to the presence of conju-
gated phenol residues34,35. Indeed, it significantly reduces amyloid beta (Aβ) and tau pathology in transgenic AD 
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mouse models35–37. Curcumin additionally labels amyloid deposits both ex vivo and in vivo by disrupting existing 
plaques and partially restoring distorted neurites in transgenic AD mice38. In addition, curcumin decreases levels 
of hyperphosphorylated tau in cells and mice by binding to fibrillar tau39. Recently, curcumin was also found to 
selectively suppress soluble tau dimers in aged Htau mice and to improve tau-mediated neuronal dysfunction 
and neuritic abnormalities in C. Elegans37,40. Hence, extensive preclinical studies have proposed curcumin as 
a potential therapeutic approach against AD and related neurodegenerative diseases, but no clinical trials have 
been successful31,41. Their failures may be due to curcumin’s poor solubility in aqueous buffers and low brain 
bioavailability following oral administration31,42–46. As a result, alternative formulations and drug delivery sys-
tems (e.g. liposomes, nanoparticles) have been formulated, as well as novel curcumin derivatives that have been 
synthesized to boost and improve its bioavailability47–53. Based on these previous studies, we decided to evaluate 
the effects of curcumin and novel curcumin derivatives on oligomeric tau species using our in vitro preparation of 
tau oligomers. In this study, we used in vitro approaches to investigate the potential neuroprotective properties of 
curcumin and newly synthesized curcumin-derived small molecules by converting the aggregation state of toxic 
tau oligomers to a non-toxic one, as assessed by cell-based assays.
Results
Curcumin effects on preformed toxic tau oligomers. We first evaluated the effect of curcumin using 
our in vitro preparation of TauO. Therefore, highly purified oligomeric tau species were incubated with and with-
out curcumin (1:5 and 1:10 molar ratio) at room temperature on an orbital shaker, under oligomerization con-
ditions. Tau oligomers in the absence and presence of curcumin were then biochemically evaluated using the 
oligomer-specific antibody, T22, and generic total tau antibodies, Tau 5 and Tau 13 (Fig. 1). Western blot analyses 
showed that curcumin interacts with tau oligomers by promoting the formation of higher molecular weight tau 
aggregates (Fig. 1A).
In addition, direct enzyme linked immunosorbent assay (ELISA) and dot blot analyses showed a signifi-
cant decrease in oligomers, as seen by the decreased T22 immunoreactivity (Fig. 1B,C). Next, the toxicity of 
curcumin-induced aggregates was assessed by 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2
-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) using the human neuroblastoma cell line, SH-SY5Y. Cells 
were exposed to untreated TauO or TauO in the presence of curcumin (final concentration 10 μM) for 24 hours. 
SH-SY5Y cell viability decreased significantly after treatment with TauO, while the treatment with curcumin 
rescued cells from TauO-induced toxicity, as seen by the higher cell viability compared to the cells exposed to 
untreated TauO (Fig. 1D). All together, these results indicate that curcumin has neuroprotective effects against 
toxic tau oligomers.
Synthesis and screening of novel curcumin analogs. To overcome the poor solubility of curcumin 
in aqueous buffers and its low cerebral bioavailability, novel curcumin derivatives were synthesized. Our 
curcumin-derived library of small molecules is comprised of four different groups of compounds with the poten-
tial to interact and modulate the aggregation state of TauO such that the progression of tauopathy can be slowed; 
this is accomplished by neutralizing their toxicity and internalization potency (Fig. 2A). In particular, heterocy-
clic derivatives with oxadiazole nucleus and Calebin-A derivatives were also included in this study due to their 
ability to interact with Aβ amyloid54–56. The complete library and synthetic details of all synthesized compounds 
are reported on Supplementary Information (SI).
All our derivatives are characterized by the removal of the β-di keto moiety that is assumed to be responsible 
for the well-known shortcomings of curcumin57. The efficacy of the curcumin derivatives was tested in vitro 
by screening the entire small compound library by group directly against preformed recombinant TauO. Our 
biochemical screening shows that the curcumin-derived small molecules can directly interact and perturb the 
aggregation state of preformed TauO (Figs. S1–S4).
Six compounds were selected due to their higher activity in modulating toxic TauO and subjected to additional 
in vitro testing to validate their effects on TauO (Fig. 2B). Synthesis of these compounds was accomplished as 
reported in Fig. 2C,D. Compounds CL3,8 were obtained through a double aldol condensation on the diacetyl of 
the appropriate aromatic aldehyde 158. Similarly, HemiC9 was obtained by means of Claisen-Schmidt Aldol con-
densation of acetone under basic conditions (Fig. 2C)59. Heterocyclic derivative CH8 was obtained in a two-step 
procedure from the corresponding cinnamic acid derivative 2 (Fig. 2D)60. Derivatives 2 were also employed for 
the synthesis of Calebin-A and its analogs Cal7,9 through a substitution reaction on iodoketone 3 as shown in 
Fig. 2D. This method allows the obtainment of target products avoiding the use of protecting groups61. One of 
the criteria used to select these small molecules was evaluating their toxicity profile. The cytotoxicity of each cur-
cumin derivative was examined by exposing the cultured human neuroblastoma SH-SY5Y cell line to a continu-
ous range of small molecule concentrations (0–800 μM) and monitoring cell survival after 24 hours of treatment 
by an MTS assay. The dose-response curves show that the curcumin derivatives have a very low-toxicity profile 
with an IC50 ranging from 54.53 μM for CL8 to 191.1 μM for Cal7 (Fig. 3).
Curcumin analogs promote tau oligomers aggregation. TauO were further characterized in vitro in 
both the absence and presence of the selected curcumin derivatives to evaluate and compare their effects on TauO 
under the same conditions (Fig. 4). Indeed, oligomeric tau species were incubated with and without curcumin 
derivatives (final conc. 5 µM) and were evaluated biochemically using the anti-oligomeric tau antibody, T22, as 
well as generic tau antibodies, Tau 5 and Tau 13. Western blot analyses revealed that curcumin-derived small 
molecules interact with TauO, resulting in decreased oligomer levels or leading to the formation of higher molec-
ular weight tau aggregates (Fig. 4A,B). Moreover, filter trap assay and direct ELISA confirmed that curcumin 
derivative interactions with TauO result in decreased oligomeric levels, as seen by the decreased T22 immuno-
reactivity, while no changes were observed in total tau levels as detected by Tau 5 immunoreactivity. In addition, 
3Scientific RepoRtS |         (2019) 9:19011  | https://doi.org/10.1038/s41598-019-55419-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
a quantitative reduction of oligomeric tau, upon treatment with curcumin derivatives, was also evaluated by 
sandwich ELISA using T22 as capture antibody and Tau 5 as detection antibody (Fig. 4C–E).
Biophysical characterization of curcumin derivatives-induced aggregates. In addition, we fur-
ther investigated the effects of curcumin derivatives on tau oligomers by biophysically characterizing curcumin 
derivative-induced aggregates (Fig. 5). Fast protein liquid chromatography (FPLC) was used to purify tau oli-
gomers, detecting a main peak at ~120–150 kDa (tau dimer/trimer) as seen in Fig. 5A. Moreover, to gain more 
insights into the structure and distribution of tau aggregates upon treatment with the curcumin derivatives, tau 
aggregates were analyzed by size-exclusion chromatography showing that the resultant tau aggregates have an 
higher molecular weight peaks as compared to the untreated tau oligomers (Fig. 5B). The morphology of tau 
oligomers was also evaluated by Atomic Force Microscopy (AFM) before and after treatment with the curcumin 
derivatives (Fig. 5C). AFM images of untreated tau oligomers displayed their classically homogeneous spherical 
morphology with the majority of the oligomers with a high of 3.36 nm as shown by the size distribution his-
togram (Fig. 5D). AFM analyses of TauO in the presence of the curcumin-derived small molecules show that 
preformed tau oligomers are converted into larger tau aggregates as seen in Fig. 5E,F. These data are consistent 
with Thioflavin T (ThT) and the 4,4′-dianilino-1,1′-binaphthyl-5,5′-disulfonic acid, dipotassium salt (bis-ANS) 
fluorescence assays that showed no fibril formation after incubation with curcumin derivatives and decreased 
binding of hydrophobic oligomers with bis-ANS, respectively, as shown in Fig. 5G,H. Moreover, both negative 
Figure 1. Biochemical and cytotoxicity analyses of oligomeric tau treated with curcumin and untreated control. 
(A) Western blot analyses of tau oligomers probed with the oligomeric tau antibody, T22 and generic total 
tau antibodies, Tau 5 and Tau 13. Curcumin interacts and alters the aggregation states of preformed TauO. 
(B) ELISA analysis of oligomeric tau treated with increased concentration of curcumin shows a significant 
decrease in T22 immunoreactivity as compared to the untreated TauO. (C) Dot blot analysis show decreased 
levels of oligomeric tau in the presence of curcumin. (D) Viability percentage of cultured SH-SY5Y human 
neuroblastoma cells exposed to 2 µM TauO or 2 µM TauO pre-incubated with curcumin and controls. SH-SY5Y 
cells given TauO pretreated with curcumin had significantly higher cells viability when compared to TauO alone 
and Ctrl. Data in B and D were compared by one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparison test: **p < 0.01, ***p < 0.001. Bars and error bars represent the mean and standard 
deviation.
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and positive controls were used, and readings were corrected for the background fluorescence to account for any 
intrinsic fluorescence of the compounds in the bis-ANS and ThT measurements. Taken together, these results 
suggest that curcumin derivatives decrease the levels of tau oligomers, affecting their morphology by promoting 
the formation of larger tau aggregates.
Curcumin analogs rescue tau oligomers-associated neurotoxicity in neuronal cultures. Next, 
TauO-associated toxicity was assessed using the human neuroblastoma cell line, SH-SY5Y (Fig. 6). Cells were 
exposed for 24 hours to increasing concentrations of TauO (0.5–2 µM). The toxicity of TauO was evaluated in 
a lactate dehydrogenase (LDH)-based assay, showing a dose-dependent cytotoxicity of TauO, as the amount of 
LDH released from damaged cells is indicative of cellular cytotoxicity and cytolysis (Fig. 6A). Furthermore, we 
investigated the ability of curcumin derivatives to rescue cells from TauO-induced toxicity. SH-SY5Y cells were 
exposed to 2 µM TauO or TauO in the presence of curcumin derivatives. Interestingly, cells incubated with TauO 
in the presence of curcumin derivatives had a significantly lower LDH release as compared to those cells exposed 
Figure 2. Structure of curcumin and newly synthesized curcumin derivatives. (A) The library of our curcumin 
derivatives consists of four different classes: Hemi-curcuminoids (HemiC); Curcumin-like (CL); Heterocyclic 
curcumin-like (CH) and Calebin-A derivatives (Cal). (B) Curcumin derivatives showing higher activity 
in modulating the aggregation of preformed tau oligomers and selected for additional in vitro testing. (C) 
Synthesis of compound CL3,8 and HemiC9. (D) Synthesis of compound CH8, Cal7,9.
Figure 3. Curcumin derivatives effects on cell viability. Curcumin derivatives cytotoxicity on human 
neuroblastoma SH-SY5Y cell line was assessed by an MTS assay to determine the IC50 values for CL3, CL8, 
CH8, HemiC9, Cal7 and Cal9 following treatment with increasing concentration of the compounds (0–
800 μM) for 24 hours. Values are presented as the mean ± SD (n = 3).
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to untreated TauO (Fig. 6B). In addition, the toxicity of TauO in the absence and presence of curcumin analogs 
was also evaluated by performing an apoptosis/necrosis assay in SH-SY5Y cells. The treatment was followed 
by fluorescence live cell imaging to monitor apoptotic, necrotic and viable cells combined simultaneously with 
bright field microscopy to better visualize and evaluate the details and morphology of viable cells in comparison 
to those undergoing apoptosis and cell death (Fig. 6C). An early event in apoptosis is the phosphatidylserine (PS) 
Figure 4. Biochemical analyses of oligomeric tau with and without curcumin derivatives. (A) Western blot 
of tau oligomers in the absence and presence of curcumin analogs (final concentration 5 μM) probed with 
the oligomeric tau antibody, T22 and total tau antibodies, Tau 5 and Tau 13 and the control anti-Aβ antibody, 
6E10. (B) The incubation with the compounds modulates the aggregation states of preformed tau oligomers 
as seen by T22 quantification analysis. (C,D) Filter Trap assay of tau oligomers alone and pretreated with 
curcumin derivatives probed with T22 and Tau 5. Curcumin-derived small molecules alter the aggregation 
pathways of tau oligomers resulting in decreased T22 immunoreactivity as compared to the untreated TauO. 
(E) ELISA analyses shows that the selected compounds decrease tau oligomer levels as seen by the reduced T22 
immunoreactivity and no significant changes in total tau protein as assessed by Tau 5 antibody. The reduction 
of tau oligomers was confirmed by sandwich ELISA, using T22 as capture antibody and Tau 5 as detection 
antibody. Data in B, D and E were compared by one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparison test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Bars and error bars represent the 
mean and standard deviation.
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exposure from the inner to the outer side of the plasma membrane that was detected by staining with Apopxin, 
while necrotic and viable cells were stained with 7-Aminoactinomycin D (7-AAD) and CytoCalcein Violet 450, 
respectively. The PS translocation precedes the loss of membrane integrity which accompanies the later stages 
of cell death resulting from either apoptotic or necrotic processes. The fluorescence microscopy observations 
confirmed the previous toxicity screens. Indeed, SH-SY5Y cells exposed to TauO alone showed significant cell 
shrinkage and cell death as we observed cells positive to Apopxin signal and few also to 7-AAD and an overall 
decreased number of live cells (blue) compared to either the control cells (Ctrl) or those cells that were treated 
with TauO in the presence of curcumin-derived small molecules. Altogether, these observations suggest that the 
selected curcumin derivatives interact and subsequently convert the toxic TauO into higher molecular weight 
aggregates, thereby modulating their toxicity.
Figure 5. Biophysical characterization of tau oligomers with and without curcumin derivatives. (A) FPLC 
chromatogram of tau oligomers showing that the main peak is ~120–150 kDa (tau dimer/trimer). (B) SEC 
chromatograms of tau oligomers alone and in the presence of curcumin derivatives. (C) Atomic Force 
Microscopy images of TauO and TauO after treatment with 5 μM of curcumin derivatives for CL3, CL8, CH8, 
HemiC9, Cal7 and Cal9; Scale bars = 100 nm. (D) Size distribution histogram of TauO shows that tau oligomers 
have an average height of 3.36 nm. (E,F) AFM analyses shows the ability of the compounds to modulate TauO 
aggregation states converting TauO into much larger aggregates as seen by modulation of tau aggregate heights 
(E) and sizes (F). (G,H)Tau oligomers alone or in the presence of 5 μM of curcumin derivatives were assessed 
by Thioflavin T and bis-ANS spectroscopy. Thioflavin T spectroscopy analysis (G) show no presence of fibrils 
formation after incubation with the compounds and preformed oligomers pretreated with curcumin analogs 
show reduced binding with bis-ANS as compared to untreated TauO (H). Data in (E–H) were compared by 
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test: *p < 0.05; **p < 0.01; 
***p < 0.001. Bars and error bars represent the mean and standard deviation.
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In addition, to further confirm our findings and gain a better understanding of the protective role of cur-
cumin derivatives, internalization screens were carried out in human neuroblastoma cell culture. SH-SY5Y cells 
were treated with a sub-lethal concentration (0.5 μM) of tau oligomers in the absence and presence of curcumin 
compounds and then imaged by fluorescence microscopy (Fig. 7). Tau oligomers were observed in both the 
plasma membranes and in the cytoplasm, indicating extensive cellular internalization of TauO. Furthermore, cells 
exposed to untreated TauO, exhibit extensive loss of plasma membrane integrity, reflecting the toxic effect of tau 
oligomers. Excitingly, cells that were treated with TauO in the presence of curcumin derivatives show a significant 
reduction in the percentage of area positive of TauO staining (Fig. 7B). Immunofluorescence analysis showed that 
the tau species, resulting from the incubation with the curcumin derivatives, mostly co-localize with the plasma 
membrane, as shown by PCC graph (Fig. 7C). Altogether, the data implies that curcumin derivatives-induced 
aggregates are less prone to be internalized by the cells, thereby elucidating their reduced cytotoxicity. The toxicity 
of the curcumin derivatives-induced aggregates was also evaluated by using primary cortical neurons isolated 
Figure 6. Curcumin derivatives-induced aggregates cytotoxicity in human neuroblastoma cell line. (A) Dose-
dependent cytotoxicity of TauO in SH-SY5Y cells after 24 hours of treatment. (B) SH-SY5Y cells cytotoxicity 
after exposure to 2 µM TauO, or 2 µM TauO in the presence of curcumin derivatives (final concentration 5 µM) 
and untreated control (Ctrl). Cells exposed to TauO had significantly higher LDH release as compared to the 
untreated control or cells treated with TauO in the presence of the compounds. Each experiment was performed 
in triplicate (n = 3). (C) SH-SY5Y cells treated for 24 hours with 2 µM of TauO or TauO in the presence 
curcumin derivatives were incubated with Apopxin to detect apoptosis (green), 7-AAD for necrosis (red) and 
CytoCalcein Violet 450 to detect viable cells (blue) and imaged by immunofluorescence microscopy. Scale 
bar = 100 µm. Data in A and B were compared by one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparison test: **p < 0.01, ****p < 0.0001. Bars and error bars represent means and standard 
deviations performed.
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from embryos of Htau mice, expressing non-mutant human tau. Primary neurons are an approximate representa-
tion of the cellular physiology, genetic expression and protein profile in vivo, providing a more appropriate model 
for drug targeting validation. Therefore, neurons were exposed to tau oligomers alone or in the presence of cur-
cumin derivatives (Fig. 8). Cell viability significantly decreased after treatment with untreated TauO, while treat-
ment with curcumin derivatives significantly reduced their toxicity as seen by the higher level of cell viability, 
as assessed by MTS assay (Fig. 8A). Furthermore, curcumin derivatives were also incubated with Aβ oligomers 
(AβO). The toxicity screens in primary neurons showed that the curcumin compounds were not able to rescue 
neurons from Aβ oligomer-induced toxicity (Fig. 8B). Moreover, to further investigate and gain an enhanced 
understanding of curcumin derivatives effects, primary cortical neurons were treated with TauO labeled with 
Alexa Fluor-568, or TauO labeled with Alexa Fluor-568 in the presence of curcumin derivatives. Cortical neurons 
were immunostained with the mature neuronal marker β-III Tubulin (green) and DAPI for nuclei (blue) and 
imaged by fluorescence microscopy (Fig. 8C). Interestingly, TauO were observed in the cell bodies and projec-
tions of neurons exposed to untreated TauO, indicating that TauO were extensively internalized by the neurons. 
On the other hand, immunofluorescence images of neurons treated with TauO in the presence of curcumin deriv-
atives show a significant reduction in area positive to TauO, suggesting that the resulting tau aggregates are less 
readily internalized by the cells, thus confirming their reduced associated neurotoxicity. In addition the effects of 
the selected curcumin analogs have been evaluated in primary cortical neurons at 2, 12 and 24 hours showing to 
have no toxic effects at 5 µM as assessed by LDH and MTS assay (Fig. 8D,E).
Figure 7. Representative epifluorescence images of human SH-SY5Y neuroblastoma cells after treatment with 
TauO or TauO in the presence curcumin derivatives. (A) SH-SY5Y cells were treated for 2 hours with sub-lethal 
concentration (0.5 µM) of TauO in the absence and presence of curcumin derivatives (final concentration 
5 µM). Cells were immunostained with DAPI (nuclei – blue), Wheat Germ Agglutinin (WGA) – Alexa Fluor-
488 (plasma membranes – green) and TauO labeled with Alexa Fluor-568 (red represented in grey). Scale bar 
10 μm. (B) Curcumin derivative-induced aggregates are taken up less by the cells, as shown by the decreased 
fluorescence intensity of TauO in the presence of curcumin derivatives as compared to TauO. (C) PCC graph 
represents co-localization coefficient of TauO with WGA, showing a significant reduction of TauO in the 
plasma membranes when cells are exposed to TauO in the presence of compounds. Analyses were performed 
on selected regions of interest characterized by same size and comparable number of cells. Data in B and C 
were compared by one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test: 
***p < 0.001, ****p < 0.0001. Bars and error bars represent means and standard deviations performed.
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Discussion
The large body of evidence supporting the key role of tau in neurodegenerative diseases suggests the importance 
of tau as a potential target for the development of successful disease-modifying therapeutics. Unfortunately, the 
aggregation of proteins and their tendency to propagate makes the treatment of tauopathy difficult. As a result, 
Figure 8. Curcumin derivatives prevent TauO-induced toxicity in primary cortical neurons. (A)Viability 
percentage of neuronal culture exposed to 0.5 µM of TauO or 0.5 µM of TauO pre-incubated with 5 µM 
curcumin derivatives and controls for 2 hours assessed by MTS assay. Neurons exposed to TauO pretreated with 
curcumin derivatives had significantly higher cell viability as compared to those exposed to untreated TauO. 
(B) Primary neurons exposed to 0.5 µM of Aβ oligomers, 0.5 µM of Aβ oligomers pre-incubated with 5 µM 
curcumin derivatives and controls. Neuronal cells treated with AβO in the presence of curcumin derivatives 
show no changes in cell viability as compared to untreated AβO, suggesting that the selected curcumin 
derivatives are not able to rescue cells from AβO-induced toxicity. (C) Representative epifluorescence images 
of cortical neurons exposed to TauO labeled with Alexa Fluor-568 or TauO labeled with Alexa Fluor-568 in 
the presence of curcumin analogs. Neurons were immunostained with βIII–Tubulin (mature neurons – green 
represented in grey), TauO (red represented in grey) and DAPI (nuclei – blue). Scale bar = 20 µm. (D-E) 
Cytotoxicity and viability percentage of neuronal culture exposed to 5 µM of curcumin derivatives over time (2, 
12 and 24 hours). Data in A, B, D and E were compared by one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparison test: *p < 0.05; **p < 0.01; ***p < 0.001. Bars and error bars represent the mean 
and standard deviation (n = 3).
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there is urgent need to diagnose these disorders earlier, and to be proactive with treatment prior to any significant 
spreading of the neurodegenerative pathology. To date, most drug development for tauopathies are focused pri-
marily on tau aggregation inhibitors or small molecules with disassembling potency34,62,63. Investigations regard-
ing treatment options should also be directed toward small molecules capable of targeting the toxic tau species 
and promoting the formation of a non-toxic aggregation state, or perhaps conformations that can be more readily 
degraded by active cellular mechanisms such as autophagy and proteasomal degradation64–68.
With the strong evidences supporting that the soluble, oligomeric tau are likely the most toxic species causing 
disease, the development of effective interventions and therapeutics to stave or reverse their propagation has 
become paramount69–73. Accelerating the fibrillization process has the potential for being an alternative approach, 
considering that it was previously used in the Aβ field74. However, it is important to confirm that these approaches 
do not inhibit fibril formation at the cost of stabilizing the toxic oligomer, as seen in many cases75. Therefore, in 
this study, we investigated the effects of newly synthesized curcumin derivatives on toxic tau oligomers. Herein, 
using fully synthetic curcumin derivatives, we report the new finding that curcumin-derived small molecules can 
interact with the highly toxic tau species. Our results suggest that the selected six curcumin analogs modulate 
the aggregation state of toxic tau oligomers by further promoting their aggregation, resulting in the formation of 
larger tau structures with decreased toxicity. Indeed, toxicity and internalization screens were assessed using both 
human neuroblastoma SH-SY5Y cell lines and cultured primary cortical neurons. Treatment with the selected 
active curcumin derivatives protected SH-SY5Y and primary cortical neurons from tau oligomer-induced neu-
rotoxicity, while the same compounds were not able to prevent neurons from AβO-induced toxicity. In addition, 
internalization screens showed that the compounds affect the tau oligomer internalization mechanism that medi-
ates their uptake by cells, a critical step for the cell-to-cell spreading and the further progression of the pathology. 
Importantly, the present study suggests that modulating the aggregation state of toxic tau oligomeric species 
through the use of small molecules, including our promising active curcumin derivatives, could be a powerful 
therapeutic strategy that targets their toxicity regardless of the multitude of factors that may be involved in the 
formation of tau oligomers.
In conclusion, the results presented here lay the groundwork for future studies to test the efficacy and ben-
eficial effects of some curcumin derivatives towards treating tauopathies. By expanding our investigation to 
disease-relevant tau oligomers,  derived from brain tissues of different tauopathies, and the effects of curcumin 
derivatives in animal models of tauopathies, will further increase our understanding of the therapeutic poten-
tial and the mechanism of action of curcumin derivatives. Our results also suggest that curcumin derivatives may 
be used as potential tau PET tracers for the early detection of tau oligomers. Indeed, they can be used to stabilize 
the highly dynamic and transient oligomers into larger and stable tau aggregates such that they may be employed 
for diagnostic purposes as imaging agents to enhance the weak imaging signals of small oligomers, providing 
opportunity for prompt interventions.
Methods
Chemistry. All solvent and reagents were used as received, unless otherwise stated. Melting points were deter-
mined on a hot-stage apparatus. 1H-NMR and 13C-NMR spectra were recorded at indicated frequencies, residual 
solvent peak was used as reference. Chromatography was performed by using silica gel (0.040–0.063 mm) and 
mixtures of ethyl acetate and petroleum ether (fraction boiling in the range of 40–60 °C) in various ratios (v/v). 
All solvent and reagents were used as received. Compounds CL358, and HemiC976, were prepared as previously 
reported. CL858, CH854,60, and Cal7,961 were prepared adapting previously reported methods. Synthetic details 
and spectroscopic characterization for all compounds are reported on SI.
Biology. Animal handling and all the experimental procedures were performed in accordance with the Guide 
for the Care and Use of Laboratory Animals (National Institutes of Health) and accordingly to the relevant guide-
lines and regulations approved by the Institutional Animal Care and Use Committee of the University of Texas 
Medical Branch (UTMB). Mice were housed at the UTMB animal care facility and maintained according to the 
U.S. Department of Agriculture standards (12 hours light/dark cycle with ad libitum access to water and food).
Preparation of tau oligomers. Recombinant tau protein (tau-441 (2N4R) MW 45.9 kDa) was expressed 
and purified as described77,78. The tau pellet was treated with 8 M urea followed by overnight dialysis against 1X 
phosphate-buffered saline (PBS) pH 7.4. Tau concentration was measured using bicinchoninic acid protein assay 
(Pierce BCA Protein Assay Kit, 23225, Thermo Fisher Scientific) and normalized to 1 mg/mL by adding 1X PBS. 
Aliquots of tau monomer in PBS were stored at -20 °C. Each 300 µL of tau stock (0.3 mg) was added to 700 µL 
of 1X PBS and incubated for 1 hour on an orbital shaker at room temperature. After shaking, the resulting tau 
oligomers were purified by fast protein liquid chromatography (FPLC, Superdex 200 Increase 10/300 column, 
Amersham Biosciences).
Preparation of tau fibrils. Recombinant tau protein (tau-441 (2N4R) MW 45.9 kDa) was expressed and 
purified as described77,78. The tau pellet was treated with 8 M urea followed by overnight dialysis against 1X 
phosphate-buffered saline (PBS) pH 7.4. Tau concentration was measured using bicinchoninic acid protein assay 
(Pierce BCA Protein Assay Kit, 23225, Thermo Fisher Scientific) and normalized to 1 mg/mL by adding 1X PBS. 
Aliquots of tau monomer were incubated with heparin (15 kDa) (1:5 molar ratio) at 37 °C on an orbital shaker at 
a speed of 30 rpm for 5 days as previously described79.
Preparation of tau oligomers in the presence of curcumin and curcumin derivatives. A volume 
of 100 μL of tau oligomers (1 µg/μL) was incubated with curcumin (1:5 and 1:10 molar ratio) and curcumin deriv-
atives (1:5 molar ratio). Compounds were dissolved in EtOH 75%/DMSO (5:1) at a final concentration of 5 mM 
and diluted in 1X PBS or ddH2O for incubation or toxicity assay (final concentration 5 μM). Tau oligomers in the 
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presence of the small molecules and controls were incubated on an orbital shaker, without stirring, for 16 hours 
under oligomerization conditions as previously described64.
Preparation of Aβ oligomers. Aβ oligomers (AβO) were prepared as previously described80. An amount 
of 0.3 mg of Aβ pellet was dissolved in 200 μL of hexafluoroisopropanol (HFIP) and incubated for 10–20 min at 
room temperature. The resulting solution was added to 700 μL of ddH2O in a siliconized Eppendorf tube with 
holes placed on top of the cap to allow the slow evaporation of HFIP. The samples were then stirred at 500 rpm 
using a Teflon-coated micro stir bar for 48 hours at room temperature in the fume hood.
Preparation of Aβ oligomers in the presence of curcumin derivatives. A volume of 100 μL of Aβ 
oligomers (0.5 µg/μL) was incubated with curcumin derivatives (final concentation 5 μM). Compounds were dis-
solved in EtOH 75%/DMSO (5:1) at a final concentration of 5 mM and diluted in 1X PBS or ddH2O for incubation 
or toxicity assay (final concentration 5 μM). Aβ oligomers in the presence of the small molecules and controls 
were incubated on an orbital shaker, without stirring, for 16 hours under oligomerization conditions as previously 
described64.
Western blotting. An amount of 3 µg of each sample were resolved on a pre-cast NuPAGE 4–12% Bis-Tris 
Gels for SDS-PAGE (NP0335BOX, Invitrogen) and transferred to nitrocellulose membranes. Then, membranes 
were blocked with 10% nonfat milk in Tris-buffered saline with very low tween 0.01% (TBS-T) overnight at 4 °C. 
After blocking, membranes were probed with T22 (1:250) for tau oligomers, Tau 5 (1:10000; 806402, BioLegend) 
and Tau 13 (1:50.000; MMS-520R, Biolegend) for total tau, and horseradish peroxidase (HRP) anti-β-Amyloid, 
6E10 for total Aβ (1:1000; 9345–02, Covance) diluted in 5% nonfat milk for 1 hour at RT. Membranes were then 
incubated with HRP-conjugated IgG anti-rabbit (1:10000, GE Healthcare) to detect T22 and anti-mouse (1:10000, 
GE Healthcare) secondary antibody to detect Tau 5 and Tau 13. ECL plus (GE Healthcare) was used for signal 
detection.
Dot Blot. Dot blot assay to detect tau oligomers in the absence or presence of small molecules was performed 
as previously described80. Briefly, 1.5 μl of each end-product reaction was applied onto nitrocellulose membranes 
and then blocked with 10% nonfat milk in TBS-T overnight at 4 °C. The next day, membranes were probed with 
the oligomer-specific tau antibodies, T22 (1:250), TOMA1(1:200) and total tau antibody, Tau 5, (1:10000) diluted 
in 5% nonfat milk for 1 hour at RT. Membranes were then incubated with HRP-conjugated IgG anti-rabbit 
(1:10000) to detect T22 and anti-mouse (1:10000) secondary antibody to detect Tau 5 and TOMA1. Blots were 
then washed three times in TBS-T and ECL plus (GE Healthcare) was used for signal detection.
Filter Trap Assay. Filter Trap assay was performed using Bio-Dot SF Microfiltration Apparatus (Bio-Rad), 
as previously described64. Briefly, 1 μg of each end-product reaction was applied onto nitrocellulose mem-
branes, previously pre-wetted with TBS-T, through the use of a vacuum based bio-slot apparatus. Membranes 
were then blocked with 10% nonfat milk in TBS-T overnight at 4 °C. Next day, membranes were probed with 
the oligomer-specific tau antibodies, T22 (1:250) and TOMA1(1:200) and total tau antibody, Tau 5 (1:10000) 
diluted in 5% nonfat milk for 1 hour at RT. Membranes were then incubated with HRP-conjugated IgG anti-rabbit 
(1:10000) to detect T22 and anti-mouse (1:10000) secondary antibody to detect Tau 5 and TOMA1. Membranes 
were then washed three time in TBS-T and ECL plus (GE Healthcare) was used for signal detection.
Direct ELISA. ELISA assay was conducted as previously described80. Briefly, 96 well plates (Nunc 
Immobilizer, Amino Plates and Modules, 436006, Thermo Fisher Scientific) were previously coated with 1.5 μL 
of tau oligomers in the presence or absence of curcumin derivatives using 50 μL of 1X PBS, pH 7.4, as coating 
buffer. After washing three times with TBS-T, plates were blocked for 2 hours at room temperature with 120 µL of 
10% nonfat milk in TBS-T. Plates were then washed three times with TBS-T, and probed with 100 μL of primary 
antibodies for 1 hour at room temperature, T22 (diluted 1:250 in 5% nonfat milk in TBS-T) and Tau 5 (diluted 
1:10000 in 5% nonfat milk in TBS-T). Plates were then washed three times with TBS-T and incubated with 100 μL 
of HRP-conjugated anti-rabbit or anti-mouse IgG, diluted 1:10000 in 5% nonfat milk in TBS-T, for 1 hour at 
room temperature. Plates were washed three times with TBS-T and developed with 3,3,5,5-tetramethylbenzidine 
(TMB + Substrate- Chromogen, S1599, Dako) The reaction was stopped using 100 μL of 1 M HCl and absorbance 
was read at 450 nm using POLARstar OMEGA plate reader. All experiments were performed in triplicate.
Sandwich ELISA. Sandwich ELISA assay was conducted as previously described81. Briefly ELISA plates 
(Nunc Immobilizer Amino Plate, 442404, Thermo Fisher Scientific) were coated with the capture antibody, T22 
(1:250) diluted in sodium bicarbonate buffer, pH 9.6. The plate was incubated at 4 °C overnight. The following 
day, after washing two times with TBS-T, plates were blocked for 2 hours at 37 °C with 120 µL of 10% nonfat milk 
in TBS-T. The plate was then loaded with 2 µg of recombinant tau oligomers in PBS and added to each well for 
90 minutes at 37 °C. Plates were then washed three times with TBS-T, and probed with 100 μL of anti-tau anti-
body, Tau 5 (diluted 1:10000 in 5% nonfat milk in TBS-T) for 1 hour at room temperature. After washing three 
times with TBS-T, plate were incubated with of 100 μL of HRP-conjugated anti-mouse IgG, diluted 1:10000 in 5% 
nonfat milk in TBS-T, for 1 hour at room temperature. Plates were washed three times with TBS-T and developed 
with 3,3,5,5-tetramethylbenzidine (TMB + Substrate- Chromogen, S1599, Dako). The reaction was stopped using 
100 μL of 1 M HCl and absorbance was read at 450 nm using POLARstar OMEGA plate reader. All experiments 
were performed in triplicate.
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Size exclusion chromatography. Tau oligomers alone and in the presence of curcumin derivatives were 
analyzed using AKTA Explorer system fitted with a Superdex 200 Increase 10/300 GL Column. Degassed deion-
ized water was used as mobile phase with a flowrate of 0.5 mL/min. Gel filtration standard (Bio-Rad 51-1901) was 
used for calibrations. Samples were resolved using absorbance at 280 nm.
Morphological analysis of TauO by AFM. Tau oligomers were characterized by AFM as previously 
described79,80,82. Briefly, samples were prepared by adding 5 µL tau oligomers in the absence or presence of cur-
cumin derivatives onto freshly-cleaved mica and allowed to adsorb to the surface. Mica were then washed three 
times with deionized water to remove unbound protein and impurities and then air-dried. Samples were then 
imaged with a Multimode 8 AFM machine (Veeco, CA) using a non-contact tapping method (ScanAsyst-Air). 
AFM analyses were performed using the particles analysis tool of the NanoScope Analysis v1.20rl AFM data 
processing software.
Bis-ANS and Thioflavin T (ThT) Fluorescence. Fluorescence spectroscopy was performed as previ-
ously described64. Samples were prepared by adding 2 µL of protein (0.3–0.5 µg/µL) and 248 µL of 10 µM bis-ANS 
(4,4′-dianilino-1,1′-binaphthyl-5,5′-disulfonic acid)(B153, Invitrogen), prepared in 100 mM glycine-NaOH 
buffer (pH 7.4), in a clear bottom 96-well black plate. Each experiment was performed in triplicate. The bis-ANS 
fluorescence intensity was measured at an emission wavelength of 520 nm upon excitation at 380 nm. For the 
ThT assay, samples were prepared using 2 µL of protein (0.3–0.5 µg/µL) and 248 µL of 5 µM ThT (T3516, Sigma), 
dissolved in 50 mM glycine-NaOH buffer (pH 8.5). Each experiment was performed in triplicate. ThT fluores-
cence intensity was recorded at an emission wavelength of 490 nm upon excitation at 440 nm using a POLARstar 
OMEGA plate reader (BMG Labtechnologies). Fluorescence spectra of the following solutions were measured 
as negative controls for both dyes (bis-ANS and ThT): dye alone, dye + vehicle. In addition, fluorescence spectra 
of dye + curcumin derivatives were measured to avoid any false positive readings due to the eventually intrinsic 
fluorescent properties of curcumin derivatives. Each reading was corrected for the corresponding background 
fluorescence.
Primary cortical neurons. Primary cortical neurons from transgenic mice expressing human full-length 
tau were prepared and maintained as previously described83. Briefly, cortical neurons were isolated from embryos 
at embryonic day 16–18 using Accutase solution (A6964, Sigma). Dissociated neurons were plated at a density 
of 30 × 104 cells/well in 96-well plates containing high glucose Dulbecco’s Modified Eagle Medium (DMEM;10–
013-CV, Corning) supplemented with 2% B27 (A3582801, Gibco), 10,000 units/mL penicillin, 10,000 μg/mL 
streptomycin, and 25 μg/mL Amphotericin B (Gibco). After 2 hours, plating medium was removed from cells 
and replaced with Neurobasal medium (12348017, Gibco) plus 2% B27, 0.5 mM GlutaMax (35050-061, Gibco), 
10,000 units/mL, 10,000 μg/mL streptomycin, and 25 μg/mL Amphotericin B supplement. Cells were grown for 
10–12 days in vitro before experiments and 50% of media changes were performed every 3 days. On day 10, neu-
ronal cultures were treated with 0.5 μM tau oligomers alone and in the presence of curcumin derivative (at final 
concentration 5 μM) for two hours. Cell viability was assessed by MTS assay.
Cell toxicity assays. MTS. Human neuroblastoma SH-SY5Y cells (ATCC CRL-2266) were maintained 
in DMEM and grown to confluence in 96-well plates as previously described64. Cells (≈10,000 cells /well) were 
treated with 2.0 µM tau oligomers and 2.0 µM tau oligomers incubated with 5 µM of curcumin or curcumin deriv-
atives for 24 hours. The dose-response curve was used to calculate the concentration of the compound required 
for 50% inhibition of cell viability (IC50).
Primary neurons were treated with 0.5 µM tau oligomers or 0.5 µM tau oligomers pre-incubated with 5 µM of 
curcumin derivatives for 2 hours. Primary neurons were also treated with 5 µM of curcumin derivatives and cell 
viability was assessed over the time at 2, 12 and 24 hours by evaluating LDH release of the cells.
Cell viability was corrected by the vehicle background. All measurements were performed in triplicate. The 
cytotoxic effect was determined using MTS assay (G3582, Promega) for assessing cell viability following the man-
ufacturers’ instructions. Optical density (OD) was measured at 490 nm with POLARstar OMEGA plate reader 
(BMG Labtechnologies). Cell viability was calculated as the percentage of the OD value of treated cells compared 
to untreated controls, according to the following equation: Viability = (OD SAMPLE/OD CONTROL) × 100%.
LDH. Human neuroblastoma SH-SY5Y cells were cultured and treated for measuring cytotoxicity using LDH 
release assay (Cytotoxicity Detection KitPLUS-LDH, 04744926001, Roche) following the manufacturers’ instruc-
tions as previously described80,84,85. Briefly, cells were maintained in DMEM and grown to confluence in 96-well 
plates. Cells (≈10,000 cells /well) were treated for 24 hours with 2.0 µM TauO or 2.0 µM TauO incubated with 
curcumin derivatives (final concentration 5 µM) and assessed by LDH assay.
Primary neurons were treated with 5 µM of curcumin derivatives and assessed their cytotoxicity over the time 
at 2, 12 and 24 hours by evaluating LDH release.
OD was measured at 490 nm with POLARstar OMEGA plate reader (BMG Labtechnologies). All measure-
ments were performed in triplicate and corrected by the vehicle background.
Immunofluorescence – SH-SY5Y. SH-SY5Y cells were maintained in DMEM and grown to confluence 
using poly-L-lysine coated coverslip in 24-well plates as previously described86,87. Cells (≈20,000 cells /well) were 
treated for 1 hour with 0.5 µM TauO labeled with Alexa Fluor-568 or 0.5 µM TauO labeled with Alexa Fluor-568 
(A20003, Invitrogen) pretreated with 5 µM of curcumin derivatives. After washing off unbound proteins, cells 
were immunostained with 5 μg/mL Wheat Germ Agglutinin (WGA) Alexa Fluor-488 (W11261, Invitrogen) for 
10 min followed by fixation in chilled methanol. After washing three times with 1X PBS, cells were permeabilized 
with 0.25% Triton-X 100, diluted in 1X PBS for 10 min. Cells were then washed three times with 1X PBS (10 min 
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each) and mounted using Prolong Gold Antifade mounting media with DAPI (P36935, Invitrogen). Slides were 
then dried in fume hood. Cells were imaged with Keyence BZ-800 Microscope using standard filters for DAPI, 
GFP and Texas Red channels and analyses have been conducted using BZ-X Analyzer software. Nikon 100X oil 
immersion objective was used to capture images.
Apoptosis analysis – fluorescence microscopy assay. SH-SY5Y cells were maintained in DMEM 
and grown to confluence using poly-L-lysine coated coverslip in 24-well plates as previously described86,87. Cells 
(≈20,000 cells /well) were treated for 24 hours with 2 µM TauO or 2.0 µM TauO incubated with curcumin deriv-
atives (final concentration 5 µM). After washing off unbound proteins, cellular apoptosis/necrosis was evaluated 
by using an Apoptosis/Necrosis Detection kit (ab176749, Abcam). Cells were incubated with Apopxin to detect 
apoptosis, 7-AAD for necrosis and CytoCalcein Violet 450 to detect live cells, for 30 min at room temperature. 
After washing, cells were imaged with Keyence BZ-800 Microscope using standard filters for DAPI, GFP and 
Texas Red channels. Nikon 20X objective was used for capturing images.
Immunofluorescence – primary cortical neurons. Primary cortical neurons from C57BL/6 mice 
(Jackson Laboratory, stock#000664) were plated at a density of 1 × 106 cells/mL using poly-L-lysine coated cov-
erslip in 24-well plates as previously described83. Cortical neurons were treated for 1 hour with 0.5 µM TauO 
labeled with Alexa Fluor-568 or 0.5 µM TauO labeled with Alexa Fluor-568 pretreated with 5 µM of curcumin 
derivatives. After washing off unbound proteins, cells were fixed in 4% paraformaldehyde for 15 min at room 
temperature. Neurons were then washed three times with 1X PBS (10 min each) and permeabilized with 0.25% 
Triton-X 100, diluted in 1X PBS for 10 min. After washing three times with 1X PBS, neurons were blocked with 
5% goat serum for 1 hour. Neurons were then immunostained overnight with the mature neuronal marker, β-III 
Tubulin (1:1000; ab78078, Abcam) at 4 °C. The next day, neurons were washed three times with1X PBS and incu-
bated with goat anti-mouse IgG Alexa Fluor-488 (1:500, Thermo Fisher Scientific) for 1 hour at room tempera-
ture. After washing with 1X PBS, neurons were mounted using Prolong Diamond Antifade mounting media with 
DAPI (P36966, Invitrogen). Slides were then dried in fume hood. Cortical neurons were imaged with a Keyence 
BZ-800 Microscope using standard filters for DAPI, GFP and Texas Red. Nikon 100X oil immersion objective 
was used to capture images.
Statistical analysis. Western blot and filter trap assay signals were quantified using ImageJ. All data col-
lected from Western blot, filter trap assay, ELISA as well as cell toxicity assays, were subjected to statistical anal-
yses and compared by one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test 
using GraphPad Prism 6.01 software. Results were considered statistically significant at p < 0.05. Each experiment 
was performed in triplicate (n = 3). Image J was used for immunofluorescence quantifications and integrated 
densities were plotted as bar graphs expressed as mean ± standard deviation. To measure co-localization from 
immunofluorescence, we used Pearson Correlation Coefficient (PCC). Analyses were conducted for each condi-
tion in five different selected regions of interest characterized by same size and comparable number of cells. All 
data collected from fluorescence assays (Immunofluorescence, bis-ANS and Thioflavin T spectroscopy binding 
assays) were subjected to statistical analyses and compared by one-way analysis of variance (ANOVA) followed 
by Dunnett’s multiple comparison test using GraphPad Prism 6.01 software.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable 
request.
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